Sharma Luv, Gupta Sumiti, Chopra Lalit, Dhamija Pooja
Acad Forensic Pathol. 2022 Jun;12(2):58-64. doi: 10.1177/19253621221106885. Epub 2022 Jun 15.
In the wake of second wave of coronavirus disease (Covid-19), an increased number of mucormycosis cases were reported by the Ministry of Health and Family Welfare in India. A total of 45 432 cases of mucormycosis were reported till mid-July 2021, with 4252 fatalities. Mucormycosis and other fungal infections are most commonly seen as an opportunistic infection. They are found in those with low underlying immunity either due to a diabetes, cancers particularly hematological malignancies, and so on, or as a side effect of prolonged/irrational use of certain drugs like steroids, immunosuppressive drugs for management of other disorders including Covid-19. The Health Authorities in India stated that although it is not a new disease, its true incidence during the beginning of the second wave was unknown as it was not a notifiable disease. As per reports, the most common presentations of mucormycosis included rhinocerebral (77.6%), cutaneous (4.3%), and pulmonary (3.0%). We present a case of pulmonary mucormycosis and pneumonitis in a Covid-19 positive patient brought for autopsy. The patient was an under trial prisoner sent for treatment to our facility who was reported Covid positive.
在新冠疫情第二波来袭之后,印度卫生和家庭福利部报告的毛霉菌病病例有所增加。截至2021年7月中旬,共报告了45432例毛霉菌病病例,其中4252例死亡。毛霉菌病和其他真菌感染最常见的是机会性感染。它们见于那些由于糖尿病、癌症尤其是血液系统恶性肿瘤等导致基础免疫力低下的人群,或者是由于长期/不合理使用某些药物(如类固醇、用于治疗包括新冠在内的其他疾病的免疫抑制药物)的副作用。印度卫生当局表示,尽管这不是一种新疾病,但在第二波疫情开始时其真实发病率未知,因为它不是法定报告疾病。据报告,毛霉菌病最常见的表现包括鼻脑型(77.6%)、皮肤型(4.3%)和肺型(3.0%)。我们报告一例新冠阳性患者尸检时发现的肺毛霉菌病和肺炎病例。该患者是一名候审囚犯,被送往我们的机构接受治疗,报告新冠检测呈阳性。